Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2010

View Archived Issues

Solithromycin shows potential against Plasmodium spp. and Mycobacterium leprae

HM-A42 ameliorates disease symptoms in models of asthma, RA and MS

First-in-human data presented on OMP-21M18 in solid tumors

CTAP-201 shows promise in patients with secondary hyperparathyroidism on hemodialysis

Anacetrapib is efficacious and safe in phase III DEFINE trial

Resolvyx Pharma divulges novel resolvin agents for ophthalmic disorders

Abbott discloses new agents for HCV infections

Boehringer Ingelheim and f-star collaborate to discover therapeutic antibodies

ImmunGene receives U.S. government grant for antibody-cytokine fusion technology

D-3263 HCl may stabilize disease in patients with advanced prostate cancer

Experiments illuminate mechanism of action of CXB-909

Convergence Pharma and Selcia collaborate on drug candidates for chronic pain

U.S. DoD recommends funding development of STA-9584 for prostate cancer

CIS Bio withdraws E.U. marketing authorization for NeoSpect

Omthera agrees with FDA on special protocol assessment for Epanova trial

Neurocrine Biosciences completes Daisy Petal trial of elagolix in endometriosis

Mimetogen Pharma's MIM-D3 enters phase II trial in dry eye syndrome

Ono Pharma announces highlights of first half fiscal year 2010

Basilea Pharma begins phase I trial of BAL-30072 for in-hospital infections

Bionor Pharma reverses decision to terminate development of Vacc-4x

Evotec and Merck KGaA join to develop preclinical candidates for neurological disease

FDA places Helix BioPharma's phase II/III IND application for topical interferon alfa-2b on hold

Nerviano Medical Sciences claims new HSP 90 inhibitors

New modulators discovered of metabotropic glutamate mGlu5 receptor

New Juvista formulation for children significantly improves scar appearance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.